REDACT Act
Summary
The REDACT Act (S.4977) is an early-stage bill introduced by Sen. Booker that would create a private cause of action for victims if their personally identifiable information is disclosed in documents released under the Epstein Files Transparency Act. It authorizes no spending and is at the earliest legislative stage, with no cosponsors and a companion bill in the House. No direct market impact is identifiable.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.The REDACT Act is an early-stage bill with no cosponsors and no funding authorization.
- 2.It creates a private cause of action for victims of PII disclosure under the Epstein Files Transparency Act, imposing liability on federal actors.
- 3.No publicly traded companies are directly impacted; the bill is procedural and liability-focused.
Market Implications
No market implications. The bill does not authorize spending, create contracts, or regulate any industry. It is a narrow liability provision for federal document disclosures. Retail investors should not adjust positions based on this bill.
Full Analysis
- On July 14, 2026, Sen. Cory Booker introduced S.4977, the REDACT Act, which was read twice and referred to the Senate Committee on the Judiciary. The bill is at the earliest legislative stage with no cosponsors and a companion bill (HR9679) also in committee. 2) The bill authorizes no federal spending. It creates a private right of action for victims whose PII or medical files are improperly disclosed under the Epstein Files Transparency Act, with statutory damages of $50,000 per instance plus attorney fees. This is a liability-creating mechanism, not a funding bill. 3) No convergence signals were provided in the enrichment data. 4) The bill does not target any specific public company or sector. It imposes liability on federal officers, employees, or agents for improper disclosure. No publicly traded company is directly affected. 5) The bill must pass the Judiciary Committee, then the full Senate, then the House, and be signed by the President. Given its early stage and lack of cosponsors, passage is uncertain and likely distant.
Key Legislators
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Securing America’s Defense Supply Chains and Ensuring Domestic Acquisition of Critical Materials
This executive order restricts waivers for foreign-sourced critical materials in defense contracts, effective January 1, 2027, and mandates that defense contractors map their supply chains from raw materials to end products, vet subcontractors for risks, and prohibit covered materials from unreliable foreign suppliers. It directs the Secretary of War to enforce strict compliance, including requiring mitigation plans for any non-compliant materials and establishing penalties for fraud or willful noncompliance.
Regulatory Relief for Certain Stationary Sources to Promote American Chemical Manufacturing Security
President Trump issued a proclamation exempting certain chemical manufacturing facilities from compliance with the EPA's HON Rule for two years, citing unavailability of required technology and national security concerns. The exemption delays emissions-control deadlines and maintains pre-HON Rule standards for listed stationary sources, invoking authority under Clean Air Act section 112(i)(4).
Advancing Regenerative Agriculture and Strengthening American Farm Resilience
This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →